February 2026

The Sovereign Discount and the End of Predictable Exclusivity The traditional pharmaceutical valuation model, long built on the bedrock of

The pharmaceutical industry is currently trapped in a pincer movement. On one side, the cost of developing a new molecular

In pharmaceutical development the term “evergreening” is a lightning rod. To its critics—consumer advocates, public health officials, and generic drug

The economic reality of contemporary drug discovery suggests that the traditional model of pharmaceutical research is becoming an exercise in

In pharmaceuticals market exclusivity is the ultimate prize. It is the golden period during which an innovator company can recoup

The Capital Efficiency of Repurposed Innovation Pharmaceutical companies face a brutal economic reality. Developing a new chemical entity now requires

The pharmaceutical industry operates on a punishing mathematical reality. In 2024, generic and biosimilar medicines accounted for 90% of all

Money is moving. The global pharmaceutical industry is currently witnessing a structural relocation of profit that will redefine the balance

The Pricing Shock: How the Inflation Reduction Act Rewrites the Valuation Rules The economic foundations of the pharmaceutical industry are